<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869165</url>
  </required_header>
  <id_info>
    <org_study_id>16.0428</org_study_id>
    <nct_id>NCT02869165</nct_id>
  </id_info>
  <brief_title>Vaginal and Urinary Microbiome Trial</brief_title>
  <official_title>The Effects of Vaginal Estrogen and a Nonhormonal Alternative on the Vaginal and Urinary Microbiome in Women With Genitourinary Syndrome of Menopause: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial looking at the effects of vaginal estrogen and a nonhormonal&#xD;
      alternative on the vaginal and urinary microbiome in women with genitourinary syndrome of&#xD;
      menopause.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study is looking at the effects of vaginal estrogen and a nonhormonal alternative&#xD;
      on the vaginal and urinary microbiome in women with genitourinary syndrome of menopause. The&#xD;
      primary objective is to describe the bacterial communities associated in the vagina and urine&#xD;
      of postmenopausal women receiving treatment for genitourinary syndrome of menopause with&#xD;
      conjugated equine estrogen topical cream (Premarin®) and a nonhormonal alternative (apricot&#xD;
      kernel oil). The participants will be randomized to either conjugated equine estrogen topical&#xD;
      vaginal cream or apricot kernel oil. They will be given validated questionnaires to assess&#xD;
      their urinary and vaginal symptoms, sexual function, quality of life, and impressions of&#xD;
      severity and improvement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal and urinary predominance of anaerobic/fastidious taxonomy of micro-organisms on genomic, microbial DNA analysis of vaginal and urinary specimens.</measure>
    <time_frame>3 months</time_frame>
    <description>Predominance (greater than 50%) in vaginal and urinary specimen of anaerobic and/or fastidious organisms in the study population compared between conjugated equine estrogen cream (Premarin) and apricot kernel oil. The primary analysis will compare the prevalence of genomic taxonomic anaerobic and/or fastidious organism predominance (&gt;50%) between the estrogen group and the non-estrogen alternative group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vaginal symptom questionnaire (VSQ)</measure>
    <time_frame>3 months</time_frame>
    <description>Change in vaginal symptoms as assessed by vulvovaginal symptom questionnaire (VSQ) at baseline and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal and urinary predominance of anaerobic/fastidious taxonomy of micro-organisms on genomic, microbial DNA analysis of vaginal and urinary specimens.</measure>
    <time_frame>3 months</time_frame>
    <description>Predominance (greater than 50%) in vaginal and urinary specimen of anaerobic and/or fastidious organisms in the study population compared between the conjugated equine estrogen cream (Premarin) and apricot kernel oil. The primary analysis will compare the prevalence of genomic taxonomic anaerobic and/or fastidious organism predominance (&gt;50%) between the baseline patients and the patients at 3 months and compare the change in prevalence in this taxonomic predominance between the two study groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Atrophic Vaginitis</condition>
  <condition>Menopause</condition>
  <condition>Recurrent Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Conjugated equine estrogen topical cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The conjugated equine estrogen topical vaginal cream 0.5 grams per vagina two times per week at nights for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apricot kernel oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One teaspoonful per vagina every night for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conjugated equine estrogen topical cream</intervention_name>
    <description>Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.</description>
    <arm_group_label>Conjugated equine estrogen topical cream</arm_group_label>
    <other_name>Premarin vaginal cream</other_name>
    <other_name>Vaginal estrogen cream</other_name>
    <other_name>CEE topical cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apricot kernel oil</intervention_name>
    <description>Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.</description>
    <arm_group_label>Apricot kernel oil</arm_group_label>
    <other_name>Natural oil</other_name>
    <other_name>Organic oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-years old&#xD;
&#xD;
          -  Women who qualify for vaginal estrogen&#xD;
&#xD;
          -  Suitability for follow-up&#xD;
&#xD;
          -  Hormonally post-menopausal status: Bilateral past ovarian removal, ≥1 year since last&#xD;
             menses if uterus in place, OR hysterectomized woman with ≥1 ovary in place AND &gt;1 year&#xD;
             of menopausal symptoms or laboratory confirmation of menopausal hormonal status (such&#xD;
             as serum follicle stimulation hormone &gt;25 IU/mL)&#xD;
&#xD;
          -  GSM symptoms (including, but not limited to genital symptoms of dryness, burning,&#xD;
             itching, and irritation; sexual symptoms of lack of lubrication, discomfort or pain,&#xD;
             and impaired sexual function; and urinary symptoms of urgency, frequency, dysuria and&#xD;
             recurrent (UTIs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18-years old&#xD;
&#xD;
          -  Known allergic reaction or other adverse reactions to Premarin® or any of its&#xD;
             components or apricot kernel oil&#xD;
&#xD;
          -  Nut allergy&#xD;
&#xD;
          -  Inability to use or place vaginal therapy due to altered mental status or anatomical&#xD;
             reasons&#xD;
&#xD;
          -  Already using vaginal estrogen or apricot kernel oil in the past two weeks&#xD;
&#xD;
          -  Known active vaginal infection (symptomatic and/or untreated) or completion of&#xD;
             treatment for bacterial vaginosis or cervical/vaginal infection within one week of&#xD;
             recruitment&#xD;
&#xD;
          -  History of recurrent or chronic bacterial vaginosis with &gt; 2 episodes per year or&#xD;
             symptoms reported for &gt; 6 months out of the last year.&#xD;
&#xD;
          -  History of active vaginal ulcerative disease (active ulcers from atrophy, herpes&#xD;
             symptoms at recruitment or herpes with &gt;2 outbreaks per year or last outbreak &lt;1month&#xD;
             ago, or vaginal laceration.&#xD;
&#xD;
          -  Chronic antibiotic or probiotic use for indications not listed.&#xD;
&#xD;
          -  Pelvic organ prolapse beyond the hymenal ring&#xD;
&#xD;
          -  Using a vaginal pessary or indwelling urinary catheter&#xD;
&#xD;
          -  Evidence of active urinary tract infection by history and symptoms, urine dipstick, or&#xD;
             urine culture on day of presentation or within last 2 weeks (defined as ≥ 100,000&#xD;
             colonies same pathologic bacteria on clean catch or 10,000 colonies on straight&#xD;
             catheter specimen)&#xD;
&#xD;
          -  Recurrent urinary tract infection 3 episodes with the last year or 2 episodes within&#xD;
             the last 6 months.&#xD;
&#xD;
          -  History of venous or arterial thromboembolism or genetic predisposition to&#xD;
             thromboembolism.&#xD;
&#xD;
          -  Ovarian cancer and estrogen responsive cancer including endometrial or breast or&#xD;
             breast cancer history of unknown hormonal status&#xD;
&#xD;
          -  Vaginal mesh erosion, sutures visible in the vagina or granulation tissue&#xD;
&#xD;
          -  Uncorrected vesicovaginal or rectovaginal fistula&#xD;
&#xD;
          -  Severe fecal or anal incontinence&#xD;
&#xD;
          -  Active vulvar dermatoses (lichen sclerosis, Behcet's disease, vulvar eczema) and on&#xD;
             chronic topical steroids.&#xD;
&#xD;
          -  Subjects with absolute contraindications to estrogen, such as diabetes mellitus with&#xD;
             end-organ damage and vascular disease, impaired liver function or a hepatic&#xD;
             hemangioma, chronic renal disease, migraine with aura, systemic lupus erythematosus&#xD;
             with prior thrombosis or vascular damage or other end-organ damage&#xD;
&#xD;
          -  Patients &lt; 6 weeks postop&#xD;
&#xD;
          -  Inability to speak or read English&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Must be genetically female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deslyn Hobson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Care Outpatient Center and Springs Medical Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202 and 40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf</url>
    <description>Age and sex composition: 2010 Census Briefs</description>
  </link>
  <link>
    <url>https://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf</url>
    <description>Organization for Economic Cooperation and Development. Health at a glance 2013: OECD indicators.</description>
  </link>
  <results_reference>
    <citation>Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2.</citation>
    <PMID>23985562</PMID>
  </results_reference>
  <results_reference>
    <citation>Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA, Kingsberg SA. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013 Jul 29;5:437-47. doi: 10.2147/IJWH.S44579. Print 2013.</citation>
    <PMID>23935388</PMID>
  </results_reference>
  <results_reference>
    <citation>Danforth KN, Townsend MK, Lifford K, Curhan GC, Resnick NM, Grodstein F. Risk factors for urinary incontinence among middle-aged women. Am J Obstet Gynecol. 2006 Feb;194(2):339-45.</citation>
    <PMID>16458626</PMID>
  </results_reference>
  <results_reference>
    <citation>Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994 Jan;61(1):178-80.</citation>
    <PMID>8293835</PMID>
  </results_reference>
  <results_reference>
    <citation>Siddiqui H, Nederbragt AJ, Lagesen K, Jeansson SL, Jakobsen KS. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol. 2011 Nov 2;11:244. doi: 10.1186/1471-2180-11-244.</citation>
    <PMID>22047020</PMID>
  </results_reference>
  <results_reference>
    <citation>Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001500. Review. Update in: Cochrane Database Syst Rev. 2016;8:CD001500.</citation>
    <PMID>17054136</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, Romero R. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 2011 Apr;118(5):533-49. doi: 10.1111/j.1471-0528.2010.02840.x. Epub 2011 Jan 20. Review.</citation>
    <PMID>21251190</PMID>
  </results_reference>
  <results_reference>
    <citation>Hummelen R, Macklaim JM, Bisanz JE, Hammond JA, McMillan A, Vongsa R, Koenig D, Gloor GB, Reid G. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One. 2011;6(11):e26602. doi: 10.1371/journal.pone.0026602. Epub 2011 Nov 2.</citation>
    <PMID>22073175</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin DH. The microbiota of the vagina and its influence on women's health and disease. Am J Med Sci. 2012 Jan;343(1):2-9. doi: 10.1097/MAJ.0b013e31823ea228. Review.</citation>
    <PMID>22143133</PMID>
  </results_reference>
  <results_reference>
    <citation>Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996 Apr;23(3):259-63.</citation>
    <PMID>8794418</PMID>
  </results_reference>
  <results_reference>
    <citation>Coyne KS, Margolis MK, Thompson C, Kopp Z. Psychometric equivalence of the OAB-q in Danish, German, Polish, Swedish, and Turkish. Value Health. 2008 Dec;11(7):1096-101. doi: 10.1111/j.1524-4733.2008.00346.x. Epub 2008 May 16.</citation>
    <PMID>18489500</PMID>
  </results_reference>
  <results_reference>
    <citation>Rogers RG, Rockwood TH, Constantine ML, Thakar R, Kammerer-Doak DN, Pauls RN, Parekh M, Ridgeway B, Jha S, Pitkin J, Reid F, Sutherland SE, Lukacz ES, Domoney C, Sand P, Davila GW, Espuna Pons ME. A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). Int Urogynecol J. 2013 Jul;24(7):1091-103. doi: 10.1007/s00192-012-2020-8. Epub 2013 Apr 30.</citation>
    <PMID>23632798</PMID>
  </results_reference>
  <results_reference>
    <citation>Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer. 2001 Jan;37(2):189-97.</citation>
    <PMID>11166145</PMID>
  </results_reference>
  <results_reference>
    <citation>Jelovsek JE, Barber MD. Women seeking treatment for advanced pelvic organ prolapse have decreased body image and quality of life. Am J Obstet Gynecol. 2006 May;194(5):1455-61.</citation>
    <PMID>16647928</PMID>
  </results_reference>
  <results_reference>
    <citation>Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33.</citation>
    <PMID>8628042</PMID>
  </results_reference>
  <results_reference>
    <citation>Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003 Jul;189(1):98-101.</citation>
    <PMID>12861145</PMID>
  </results_reference>
  <results_reference>
    <citation>Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause. 2009 Jul-Aug;16(4):735-41. doi: 10.1097/gme.0b013e318199e734.</citation>
    <PMID>19252451</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008 Jul-Aug;15(4 Pt 1):661-6. doi: 10.1097/gme.0b013e31815a5168.</citation>
    <PMID>18698279</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014 Dec;124(6):1147-1156. doi: 10.1097/AOG.0000000000000526. Review.</citation>
    <PMID>25415166</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahn DD, Ward RM, Sanses TV, Carberry C, Mamik MM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J. 2015 Jan;26(1):3-13. doi: 10.1007/s00192-014-2554-z. Epub 2014 Nov 13. Review.</citation>
    <PMID>25392183</PMID>
  </results_reference>
  <results_reference>
    <citation>Erekson EA, Yip SO, Wedderburn TS, Martin DK, Li FY, Choi JN, Kenton KS, Fried TR. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013 Sep;20(9):973-9. doi: 10.1097/GME.0b013e318282600b.</citation>
    <PMID>23481118</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Deslyn T. Hobson</investigator_full_name>
    <investigator_title>Fellow Female Pelvic Medicine and Reconstructive Surgery</investigator_title>
  </responsible_party>
  <keyword>Postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Atrophic Vaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 16, 2021</submitted>
    <returned>August 6, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

